How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
25
HCAT Quote, Financials, Valuation and Earnings
Last price:
$2.18
Seasonality move
:
-20.94%
Day range:
$2.11 - $2.34
52-week range:
$2.02 - $5.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.47x
P/B ratio:
0.46x
Volume:
721.7K
Avg. volume:
590.7K
1-year change:
-60.15%
Market cap:
$154.2M
Revenue:
$306.6M
EPS (TTM):
-$1.58
Analysts' Opinion
-
Consensus RatingHealth Catalyst, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 8 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.88, Health Catalyst, Inc. has an estimated upside of 77.75% from its current price of $2.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.75 representing 100% downside risk from its current price of $2.18.
Fair Value
-
According to the consensus of 11 analysts, Health Catalyst, Inc. has 77.75% upside to fair value with a price target of $3.88 per share.
HCAT vs. S&P 500
-
Over the past 5 trading days, Health Catalyst, Inc. has underperformed the S&P 500 by -1.08% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Health Catalyst, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Health Catalyst, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Health Catalyst, Inc. reported revenues of $76.3M.
Earnings Growth
-
Health Catalyst, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Health Catalyst, Inc. reported earnings per share of -$0.32.
Enterprise value:
234.8M
EV / Invested capital:
--
Price / LTM sales:
0.47x
EV / EBIT:
--
EV / Revenue:
0.74x
PEG ratio (5yr expected):
-0.08x
EV / Free cash flow:
-7.01x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$102.2M
Return On Assets:
-14.29%
Net Income Margin (TTM):
-34.05%
Return On Equity:
-30.29%
Return On Invested Capital:
-16.35%
Operating Margin:
-19.07%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $290M | $302.1M | $316.1M | $76.4M | $76.3M | |
| Gross Profit | $91.1M | $98M | $102.2M | $24.3M | $26.3M | |
| Operating Income | -$96M | -$63.1M | -$53M | -$12.2M | -$14.6M | |
| EBITDA | -$49.4M | -$20.1M | -$5.1M | -$2.2M | -$1.9M | |
| Diluted EPS | -$2.23 | -$1.35 | -$1.58 | -$0.24 | -$0.32 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $514M | $442.1M | $406.4M | $455.2M | $163.3M | |
| Total Assets | $845.5M | $776.2M | $712.9M | $813.1M | $587.1M | |
| Current Liabilities | $263.4M | $91.1M | $84.3M | $323.8M | $87.9M | |
| Total Liabilities | $296.3M | $336.2M | $330.5M | $458M | $255.2M | |
| Total Equity | $549.2M | $440M | $382.4M | $355M | $331.9M | |
| Total Debt | $202.1M | $244.7M | $245.9M | $361M | $168.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$28.9M | -$955K | -$12.7M | $6.2M | -$464K | |
| Cash From Investing | -$3.4M | $119.8M | -$77.6M | $7.6M | -$9.4M | |
| Cash From Financing | $3M | $114.5M | -$197.7M | $112.5M | -$537K | |
| Free Cash Flow | -$44.5M | -$15.5M | -$33.5M | $1.8M | -$5.6M | |
HCAT
Sector
Market Cap
$154.2M
$23.7M
Price % of 52-Week High
36.95%
49.4%
Dividend Yield
0%
0%
Shareholder Yield
9.15%
-1.67%
1-Year Price Total Return
-60.15%
-20.73%
Beta (5-Year)
1.733
0.502
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.21
200-day SMA
Sell
Level
$3.22
Bollinger Bands (100)
Sell
Level
2.33 - 3.05
Chaikin Money Flow
Buy
Level
4.1K
20-day SMA
Sell
Level
$2.31
Relative Strength Index (RSI14)
Sell
Level
41.98
ADX Line
Buy
Level
18.78
Williams %R
Neutral
Level
-79.1045
50-day SMA
Sell
Level
$2.43
MACD (12, 26)
Buy
Level
0.49
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Sell
Level
-1.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.045)
Sell
CA Score
(Annual)
Level (-0.7695)
Buy
Beneish M-Score
(Annual)
Level (-2.9952)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.6781)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Health Catalyst, Inc. engages in the provision of data and analytics technology and services to healthcare organizations. It operates through the Technology and Professional Services segments. The Technology segment includes its data platform, analytics applications, and support services. The Professional Services segment combines analytics, implementation, strategic advisory, outsource, and improvement services to deliver expertise to its customers. The company was founded by Steven C. Barlow and Thomas D. Burton in 2008 and is headquartered in South Jordan, UT.
Stock Forecast FAQ
In the current month, HCAT has received 3 Buy ratings 8 Hold ratings, and 0 Sell ratings. The HCAT average analyst price target in the past 3 months is $3.88.
-
Where Will Health Catalyst, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Health Catalyst, Inc. share price will rise to $3.88 per share over the next 12 months.
-
What Do Analysts Say About Health Catalyst, Inc.?
Analysts are divided on their view about Health Catalyst, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Health Catalyst, Inc. is a Sell and believe this share price will drop from its current level to $2.75.
-
What Is Health Catalyst, Inc.'s Price Target?
The price target for Health Catalyst, Inc. over the next 1-year time period is forecast to be $3.88 according to 11 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 8 analysts rate the stock a Hold.
-
Is HCAT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Health Catalyst, Inc. is a Hold. 8 of 11 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of HCAT?
You can purchase shares of Health Catalyst, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Health Catalyst, Inc. shares.
-
What Is The Health Catalyst, Inc. Share Price Today?
Health Catalyst, Inc. was last trading at $2.18 per share. This represents the most recent stock quote for Health Catalyst, Inc.. Yesterday, Health Catalyst, Inc. closed at $2.18 per share.
-
How To Buy Health Catalyst, Inc. Stock Online?
In order to purchase Health Catalyst, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get HCAT Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
HCAT
Sector
P/E ratio
--
23.26x
PEG ratio
-0.08x
-0.01x
P/B ratio
0.46x
1.77x
Price / LTM sales
0.47x
1.54x
Growth Metrics
HCAT
Sector
Revenue growth
-0.04%
3.94%
Earnings growth
-29.68%
9.72%
Revenue (5-year growth)
14.62%
6.15%
Earnings forecast
$0.10
-$0.19
Profitability
HCAT
Sector
Profitability FY 2024
$100.4M
$2.7M
Return on invested capital
-16.35%
-33.43%
Return on assets
-14.29%
-29.68%
Return on equity
-30.29%
-38.98%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
9
Balance Sheet
HCAT
Sector
Total cash
$91.5M
$25M
Short term investments
$142.4M
$23.9M
Total assets
$858.9M
$71.9M
Long term debt
$168.3M
$2.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
51
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
13
CRVL alert for Feb 4
CorVel Corp. [CRVL] is down 4.44% over the past day.
Buy
62
DVA alert for Feb 4
DaVita, Inc. [DVA] is up 6.21% over the past day.
Sell
26
IT alert for Feb 4
Gartner, Inc. [IT] is down 0.7% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
